Why Lyell Immunopharma, Inc. (LYEL) stock fell 8.6% on Friday, November 13, 2026
Lyell Immunopharma, Inc. (LYEL) closed at $14.3, down 8.57% on Friday, November 13, 2026, on volume of 236,615 shares (1.4× its 3-month average); market value about $400.0M, according to Nexqual market data (nexqual.com/moves/2026-11-13/LYEL).
What happened: primary sources
Events Nexqual found for LYEL on Friday, November 13, 2026 or the trading day before (November 12, 2026), each linked to its primary source:
- Nov 13, 2026: HC Wainwright & Co.: Target lowered, Buy, price target $45 → $39
- Nov 10, 2026: Form 4: Lee Gary K. (Chief Scientific Officer) sold 129 shares ($2,055), not under a 10b5-1 plan source
- Nov 10, 2026: Form 4: Hill Stephen J. (Chief Operating Officer) sold 88 shares ($1,402), not under a 10b5-1 plan source
- Nov 10, 2026: Form 4: Seely Lynn (President and CEO) sold 545 shares ($8,682), not under a 10b5-1 plan source
- Nov 10, 2026: Form 4: Bulis Veronica Sanchez (VP, Corporate Controller) sold 416 shares ($6,627), not under a 10b5-1 plan source
These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.
More on LYEL
LYEL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 13, 2026.
Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 18, 2026 at 20:31 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 18, 2026 at 20:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt